Polycystic ovary syndrome is one of the common reproductive endocrine diseases in women in recent years. A large number of studies have found that serum anti-Müllerian hormone levels in patients with polycystic ovary syndrome are significantly higher than those in normal women, especially in anovulatory patients with polycystic ovary syndrome. This article briefly introduces the relationship between follicular development, hyperandrogenemia, obesity, and insulin resistance in the pathological manifestations of polycystic ovary syndrome and anti-Müllerian hormone, and the application of anti-Müllerian hormone in assisted reproduction, ovarian reserve and diagnosis in patients with polycystic ovary syndrome. It aims to provide a basis for better use of anti-Müllerian in the diagnosis and treatment of polycystic ovary syndrome.
